NCT05122039 ProspectIve Cohort psoriASiS fOllow-up (PICASSO)
| NCT ID | NCT05122039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-10-20 |
| Primary Completion | 2032-10-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2021-10-20 with a primary completion date of 2032-10-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of the PICASSO-project is to facilitate future psoriasis-research in dermatology. This register biobank will enable us to perform research in the field of metabolomics, mRNA-expression, cardiovascular impact and the microbiome. The final aims are patient stratification, better insight in disease-evolution and improved understanding of markers that predispose to severe disease.
Eligibility Criteria
Inclusion Criteria: * Clinical signs of Psoriasis since \>3 years * adults (70 years old or less) and children (\>12 years old) * willing and able to understand and sign the informed consent (plus legal representative in case of a minor) Exclusion Criteria: * unwilling or unable to understand and sign the informed consent * disease duration longer than 3 years
Contact & Investigator
Tom Hillary, MD
PRINCIPAL INVESTIGATOR
Department of Dermatology, University Hospitals Leuven
Frequently Asked Questions
Who can join the NCT05122039 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 70 Years, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05122039 currently recruiting?
Yes, NCT05122039 is actively recruiting participants. Contact the research team at tom.hillary@uzleuven.be for enrollment information.
Where is the NCT05122039 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT05122039 clinical trial?
NCT05122039 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Tom Hillary, MD at Department of Dermatology, University Hospitals Leuven. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.